Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGNATURE Module 4: Encorafenib in BRAF V600 mutated tumors
NCT01981187Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jan 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib in solid tumor, hematologic malignancy, sponsored by Pfizer. Started Jan 2014; status: terminated.
02
Drugs
encorafenib
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT01981187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01981187.